This session will focus on parents’ need for clear, trusted information, the sources they rely on, where gaps exist, and how we are aiming to address them. It will also conclude with practical pointers on finding reliable information within rare disease communities, leading into the subsequent trial-focused webinars.

This session will provide an in-depth look at current frontline treatment strategies for high‑risk neuroblastoma, focusing on how therapy is delivered in the United States through COG (Children’s Oncology Group) and in Europe through SIOPEN (International Society of Paediatric Oncology Europe Neuroblastoma). The discussion will highlight key elements of the HRBL2 and ANBL2131 protocols.

This session will cover what the BEACON2 trial is, what it is trying to answer, potential side effects, future arms, and a parent advocate's perspective.

This session will provide an accessible overview of the MINT study, a clinical trial exploring the combination of MIBG therapy and PARP inhibition, which may be particularly relevant for ATRX‑driven neuroblastoma. It will cover how the study aims to address gaps in treatment for specific high‑risk neuroblastoma subgroups, such as ATRX‑driven disease, and offer insight into the transatlantic collaboration driving the trial and why this approach is essential.

This session will focus on the Bambino Gesù CAR‑T cell trial, expansion across European sites, and the importance of broadening access to these treatments. 

Session overview: This session brings together three expert‑led talks to support families at different points after treatment: understanding and using end of treatment summaries, learning about the Right to be Forgotten after childhood cancer treatment, and recognising and responding to trauma within the family. Each session provides practical guidance, reassurance, and tools to help families navigate life after treatment.

This presentation supports parents and carers looking to understand and make the most of their child’s end of treatment summary. You’ll learn what these summaries include, why they matter, and how they can guide ongoing follow-up care and self-management at home. Emily will walk through how to read the information clearly, track health needs, access ongoing support, and recognise important signs of late effects from treatment. You’ll also receive practical tips for communicating with healthcare teams and advocating for your child’s needs.

What happens to a child or young adult’s medical history once cancer treatment ends? This presentation explains the Right to be Forgotten—what it is, how it affects those who have had childhood cancer, and what it means for families in practical terms. Carina will outline how this legal protection can help safeguard privacy, reduce barriers to opportunities such as insurance or financial products, and give families greater control over future decisions. You’ll learn what steps to take to exercise this right, and how it can support those affected by cancer and their parents or caregivers in their years ahead.

This welcoming session offers compassionate, practical support for families experiencing emotional challenges after neuroblastoma treatment. Dr Haeems will explore how trauma can present in both children and parents, how it can affect everyday life, and what can help families begin to heal. The session introduces simple, actionable strategies to build resilience, guidance on creating supportive communication within the family, and suggestions for when additional professional help may be beneficial.